---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-001945"
form_type: "8-K"
ticker: "ACTU"
cik: "0001652935"
company_name: "ACTUATE THERAPEUTICS, INC."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:07:49.212870+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Actuate Therapeutics enters $50M equity line with B. Riley, can sell shares at 3% VWAP discount

## Summary
- Company may sell up to $50M of common stock to B. Riley Principal Capital II over 36 months at a 3% discount to VWAP.
- Sales are at Actuate's sole discretion; no obligation to sell any shares under the agreement.
- Beneficial ownership by B. Riley capped at 4.99%; exchange cap of 19.99% of shares outstanding unless higher threshold price met.
- Actuate paid a cash commitment fee of up to $500,000 (1% of facility) and will reimburse legal fees.
- Proceeds intended for working capital and general corporate purposes; company retains right to terminate at any time with 10 trading days' notice.

## SEC filing metadata
- accession: 0001683168-25-001945
- form_type: 8-K
- ticker: ACTU
- cik: 0001652935
- company_name: ACTUATE THERAPEUTICS, INC.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652935/000168316825001945/0001683168-25-001945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652935/000168316825001945/actuate_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-001945
- JSON: https://secwatch.observer/filing/0001683168-25-001945.json
- Plain text: https://secwatch.observer/filing/0001683168-25-001945.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.